Quantitative Subanalysis of Optical Coherence Tomography after Treatment with Ranibizumab for Neovascular Age-Related Macular Degeneration
Open accessThe DOI matches its Crossref record; 16 of the 18 references it cites were found in a registry or an index, and 2 are not checked yet.
Abstract
PURPOSE: To investigate the effects of ranibizumab on retinal morphology in patients with neovascular age-related macular degeneration (AMD) using optical coherence tomography (OCT) quantitative subanalysis. METHODS: Data from 95 patients receiving intravitreal ranibizumab for neovascular AMD were collected. StratusOCT images were analyzed using custom software that allows precise positioning of prespecified boundaries on every B-scan. Changes in thickness/volume of the retina, subretinal fluid (SRF), subretinal tissue (SRT), and pigment epithelial detachments (PEDs) at week 1 and at months 1, 3, 6, and 9 after treatment were calculated. RESULTS: Total retinal volume reached its nadir at month 1, with an average reduction of 0.43 mm(3) (P < 0.001). By month 9, this initial change had been reduced to a mean reduction of 0.32 mm(3) (P = 0.0011). Total SRF volume reached its lowest level by month 1, with an average reduction of 0.24 mm(3) (P < 0.001). This reduction lessened subsequently, to 0.18 mm(3), by month 9. There was an average 0.3-mm(3) decrease in total PED volume by month 1 (P < 0.001), and this later declined further, to 0.45 mm(3), by month 9 (P = 0.0014). Total SRT volume was reduced by an average of 0.07 mm(3) at month 1 (P = 0.0159) and subsequently remained constant. CONCLUSIONS: Although neurosensory retinal edema and SRF showed an early reduction to nadir after the initiation of ranibizumab therapy, the effect on the retina was attenuated over time, suggesting possible tachyphylaxis. PED volume showed a slower but progressive reduction. Manual quantitative OCT subanalysis may allow a more precise understanding of anatomic outcomes and their correlation with visual acuity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Keane et al 54 first suggested possible tachyphylaxis in the treatment of n-AMD after investigating retinal morphology by OCT following treatment with ranibizumab for CNV.”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [54]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 1×
“2 (3 [1–6]) 4.”
Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Avery, R. L., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., & Giust, M. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.11.019 · Cited by 1,133
Fung, A. E., Lalwani, G. A., Rosenfeld, P. J., Dubovy, S. R., Michels, S., Feuer, W. J., Puliafito, C. A., Davis, J. L., Flynn, H. W., & Esquiabro, M. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.01.028 · Cited by 972
The epidemiology of age-related macular degeneration
Klein, R., Peto, T., Bird, A., & Vannewkirk, M. R. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2003.11.069 · Cited by 932
(1991) · Archives of Ophthalmology · doi:10.1001/archopht.1991.01080090044025 · Cited by 495
Potential Public Health Impact of Age-Related Eye Disease Study Results: AREDS Report No. 11
(2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.11.1621 · Cited by 374
Errors in Retinal Thickness Measurements Obtained by Optical Coherence Tomography
SADDA, S., WU, Z., WALSH, A., RICHINE, L., DOUGALL, J., CORTEZ, R., & LABREE, L. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.10.005 · Cited by 242
Self-citationKaiser, P. K., Blodi, B. A., Shapiro, H., & Acharya, N. R. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.04.030 · Cited by 217
Cited by
Schmidt-Erfurth, U., Chong, V., Loewenstein, A., Larsen, M., Souied, E., Schlingemann, R., Eldem, B., Monés, J., Richard, G., & Bandello, F. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305702 · Cited by 639
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005139.pub3 · Cited by 520
Defining response to anti-VEGF therapies in neovascular AMD
Amoaku, W. M., Chakravarthy, U., Gale, R., Gavin, M., Ghanchi, F., Gibson, J., Harding, S., Johnston, R. L., Kelly, S., Lotery, A., et al. (2015) · Eye · doi:10.1038/eye.2015.48 · Cited by 355
Sun, X., Yang, S., & Zhao, J. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s97653 · Cited by 347
Evaluation of Age-related Macular Degeneration With Optical Coherence Tomography
Keane, P. A., Patel, P. J., Liakopoulos, S., Heussen, F. M., Sadda, S. R., & Tufail, A. (2012) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2012.01.006 · Cited by 280
Self-citation
Metadata
- Authors
- Keane, P. A., Liakopoulos, S., Ongchin, S. C., Heussen, F. M., Msutta, S., Chang, K. T., Walsh, A. C., & Sadda, S. R.
- Affiliations
- University of Southern California (US)
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2008-07-01
- Volume
- 49
- Issue
- 7
- Pages
- 3115
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- PMC
- PMC2673192
- OpenAlex
- W2051103210
- Cited by
- 145
- References
- 16
- Citations by year
- 2025: 5 · 2024: 2 · 2023: 4 · 2022: 4 · 2021: 9 · 2020: 4 · 2019: 8 · 2018: 7 · 2017: 8 · 2016: 8 · 2015: 12 · 2014: 9 · 2013: 23 · 2012: 13
- FWCI
- 9.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- National Eye Institute (P30EY003040, R21EY015914, #EY03040, R01EY014375)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- ranibizumab, neovascular age-related macular degeneration, retinal volume, subretinal fluid, pigment epithelial detachment, tachyphylaxis, intravitreal anti-VEGF therapy, retinal thickness
- MeSH terms
- Ranibizumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Body Fluids, Diagnosis, Computer-Assisted, Female, Follow-Up Studies, Humans, Macular Degeneration, Male, Middle Aged, Papilledema, Pigment Epithelium of Eye, Retina, Retinal Detachment, Retrospective Studies, Time Factors, Choroidal Neovascularization, Tomography, Optical Coherence, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Quantitative Subanalysis of Optical Coherence Tomography after Treatment with Ranibizumab for Neovascular Age-Related Macular Degeneration. https://app.cochat.ai/papers/10.1167/iovs.08-1689
- The paper
- Keane, P. A., Liakopoulos, S., Ongchin, S. C., Heussen, F. M., Msutta, S., Chang, K. T., Walsh, A. C., & Sadda, S. R. (2008). Quantitative Subanalysis of Optical Coherence Tomography after Treatment with Ranibizumab for Neovascular Age-Related Macular Degeneration. Investigative Opthalmology & Visual Science. https://doi.org/10.1167/iovs.08-1689
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.